Zevra Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$11.02

+7.41%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.26
Volume: 2.1M
Day's high: —
Day's low: —

In brief

Zevra Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $654M.
Its shares closed at $11.17 on 4 Nov 2026, up 14.1% over the past year.
From India you can buy ZVRA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zevra Therapeutics, Inc. (ZVRA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ZVRA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ZVRA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Above its 50- and 200-day averages
The 4 Nov 2026 close of $11.17 was 0.7% above its 50-day average ($11.10) and 3.7% above its 200-day average ($10.77). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 28 Apr 2026, 132 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
7.1 days to cover short interest
6.2M shares were sold short at the 15 Oct 2026 settlement, 10.5% of the 59.4M shares outstanding; covering them would take 7.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.1M shares was 2.5× the average of the 30 sessions before it (825.6K), as the price rose 8.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
In line with SPY, behind its sector fund XLV over 1 year
1 month: +4.1% (SPY −1.6%, XLV +13.5%). 3 months: +6.1% (SPY −0.4%, XLV +15.5%). 1 year: +14.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZVRA, SPY and XLV · as of 4 Nov 2026
45% of the way up its 52-week range
Closed at $11.17 on 4 Nov 2026: 25.7% below the 52-week high of $15.04 (8 Jul 2026) and 39.5% above the low of $8.01 (19 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+4.1%

6 months−0.7%

1 year+14.1%

5 years—

Newswire

About

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Website

Notable moves

July 24, 2026
−23.92%
August 5, 2024
+25.08%
July 9, 2024
+21.94%

Zevra Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$11.02

+7.41%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.26
Volume: 2.1M
Day's high: —
Day's low: —

In brief

Zevra Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $654M.
Its shares closed at $11.17 on 4 Nov 2026, up 14.1% over the past year.
From India you can buy ZVRA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zevra Therapeutics, Inc. (ZVRA) shares from India?

Do I need the price of a whole ZVRA share to invest?

How much can I invest in US stocks in a year?

Can I trade ZVRA options or futures?

Insights

Quotes run fifteen minutes behind.

Above its 50- and 200-day averages
The 4 Nov 2026 close of $11.17 was 0.7% above its 50-day average ($11.10) and 3.7% above its 200-day average ($10.77). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 28 Apr 2026, 132 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
7.1 days to cover short interest
6.2M shares were sold short at the 15 Oct 2026 settlement, 10.5% of the 59.4M shares outstanding; covering them would take 7.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.1M shares was 2.5× the average of the 30 sessions before it (825.6K), as the price rose 8.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
In line with SPY, behind its sector fund XLV over 1 year
1 month: +4.1% (SPY −1.6%, XLV +13.5%). 3 months: +6.1% (SPY −0.4%, XLV +15.5%). 1 year: +14.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZVRA, SPY and XLV · as of 4 Nov 2026
45% of the way up its 52-week range
Closed at $11.17 on 4 Nov 2026: 25.7% below the 52-week high of $15.04 (8 Jul 2026) and 39.5% above the low of $8.01 (19 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+4.1%

6 months−0.7%

1 year+14.1%

5 years—

Newswire

About

Website

Notable moves

July 24, 2026
−23.92%
August 5, 2024
+25.08%
July 9, 2024
+21.94%

Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. in brief

Above its 50- and 200-day averages

7.1 days to cover short interest

Volume 2.5× its 30-session average on 4 Nov 2026

In line with SPY, behind its sector fund XLV over 1 year

45% of the way up its 52-week range

Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. in brief

Above its 50- and 200-day averages

7.1 days to cover short interest

Volume 2.5× its 30-session average on 4 Nov 2026

In line with SPY, behind its sector fund XLV over 1 year

45% of the way up its 52-week range